← FDA DRUG APPROVALS

FDA ANDA · ANDA215675

PREGABALIN EXTENDED RELEASE

pregabalin

Sponsor: SCIEGEN PHARMS

APPLICATION
ANDA215675
TYPE
ANDA
ORIGINAL APPROVAL
2022-09-14
LATEST ACTION
2022-09-14
ROUTE
ORAL
DOSAGE FORM
TABLET, EXTENDED RELEASE
MARKETING STATUS
Discontinued

Products

PREGABALINDiscontinued
PREGABALIN 82.5MG · TABLET, EXTENDED RELEASE · ORAL
PREGABALINDiscontinued
PREGABALIN 165MG · TABLET, EXTENDED RELEASE · ORAL
PREGABALINDiscontinued
PREGABALIN 330MG · TABLET, EXTENDED RELEASE · ORAL

Approval history

2022-09-14UNKNOWN · Original · standardAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industry →GMP discipline →FDA drug shortages →FDA enforcement & recalls →

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →